Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II study of continuous vs. standard capecitabine in metastatic breast cancer
2004-002759-15Phase 4Completed
- Sponsor
- Dr. Miguel MartÃn
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of capecitabine in breast cancer (2 arms), sponsored by Dr. Miguel MartÃn. Primary endpoints: Global response rate and Tolerance and safety profile. Started May 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002759-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002759-15.